MA53742A - Molécules de liaison à l'antigène capables de se lier à cd3 et cd137 mais pas simultanément - Google Patents

Molécules de liaison à l'antigène capables de se lier à cd3 et cd137 mais pas simultanément

Info

Publication number: MA53742A
Authority: MA; Morocco
Prior art keywords: antigen; bind; binding molecules; molecules; binding
Prior art date: 2018-09-28

Application number

MA053742A

Other languages

English (en)

Inventor

Shu Feng

Shu Wen Samantha Ho

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-09-28

Filing date

2019-09-27

Publication date

2022-01-05

2019-09-27 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2022-01-05 Publication of MA53742A publication Critical patent/MA53742A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA053742A 2018-09-28 2019-09-27 Molécules de liaison à l'antigène capables de se lier à cd3 et cd137 mais pas simultanément MA53742A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2018185120		2018-09-28
JP2019104308		2019-06-04

Publications (1)

Publication Number	Publication Date
MA53742A true MA53742A (fr)	2022-01-05

Family

ID=69950671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA053742A MA53742A (fr)	2018-09-28	2019-09-27	Molécules de liaison à l'antigène capables de se lier à cd3 et cd137 mais pas simultanément

Country Status (19)

Country	Link
US (1)	US20210388087A1 (fr)
EP (1)	EP3856785A4 (fr)
JP (3)	JP7519990B2 (fr)
KR (1)	KR20210068079A (fr)
CN (1)	CN113166247A (fr)
AU (1)	AU2019347412A1 (fr)
BR (1)	BR112021005722A2 (fr)
CA (1)	CA3114154A1 (fr)
CL (1)	CL2021000739A1 (fr)
CO (1)	CO2021005528A2 (fr)
CR (1)	CR20210199A (fr)
IL (1)	IL281787A (fr)
MA (1)	MA53742A (fr)
MX (1)	MX2021003608A (fr)
PE (1)	PE20211072A1 (fr)
PH (1)	PH12021550662A1 (fr)
SG (1)	SG11202101912UA (fr)
TW (1)	TW202028238A (fr)
WO (1)	WO2020067419A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4310191A3 (fr)	2012-06-14	2024-05-15	Chugai Seiyaku Kabushiki Kaisha	Molécule de liaison à l'antigène contenant une région fc modifiée
TWI652279B (zh)	2013-11-11	2019-03-01	中外製藥股份有限公司	含改變的抗體可變區之抗原結合分子
EP4632120A3 (fr)	2014-11-11	2026-01-07	Chugai Seiyaku Kabushiki Kaisha	Bibliothèque de molécules de liaison à l'antigène comprenant une région variable d'anticorps modifié
EP3720963A4 (fr)	2017-12-05	2021-12-08	Chugai Seiyaku Kabushiki Kaisha	Molécule de liaison à l'antigène comprenant une région variable d'anticorps modifiée se liant à cd3 et cd137
EP3732195A4 (fr)	2017-12-28	2022-02-09	Chugai Seiyaku Kabushiki Kaisha	Agent thérapeutique induisant une cytotoxicité
AU2019315226B2 (en)	2018-08-03	2025-09-18	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule containing two antigen-binding domains that are linked to each other
CN113260634A (zh)	2018-09-28	2021-08-13	中外制药株式会社	包含改变的抗体可变区的抗原结合分子
PH12021552960A1 (en)	2019-07-10	2022-07-25	Chugai Pharmaceutical Co Ltd	Claudin-6 binding molecules and uses thereof
SG11202105566TA (en) *	2020-03-31	2021-11-29	Chugai Pharmaceutical Co Ltd	Immune activating multispecific antigen-binding molecules and uses thereof
JP7736688B2 (ja) *	2020-03-31	2025-09-09	中外製薬株式会社	多重特異性抗原結合分子を製造するための方法
CA3173587A1 (fr)	2020-03-31	2021-10-07	Chugai Seiyaku Kabushiki-Kaisha	Molecules multispecifiques de liaison a l'antigene ciblant dll3 et leurs utilisations
WO2023036043A1 (fr) *	2021-09-09	2023-03-16	广东东阳光药业有限公司	Molécule de liaison anti-cancéreuse et son utilisation
JP7557922B2 (ja)	2021-09-29	2024-09-30	中外製薬株式会社	Ｄｌｌ３標的多重特異性抗原結合分子の使用
JPWO2023053282A1 (fr) *	2021-09-29	2023-04-06
WO2023053272A1 (fr) *	2021-09-29	2023-04-06	Chugai Seiyaku Kabushiki Kaisha	Utilisations de molécules de liaison à un antigène multispécifiques ciblant dll3
JP7470760B2 (ja) *	2021-09-29	2024-04-18	中外製薬株式会社	がんの治療に用いるための細胞傷害誘導治療剤
CN120077072A (zh) *	2022-11-29	2025-05-30	江苏恒瑞医药股份有限公司	Cldn18.2/4-1bb结合蛋白及其医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100940380B1 (ko)	1999-01-15	2010-02-02	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
EP3342782B1 (fr)	2004-07-15	2022-08-17	Xencor, Inc.	Variantes optimisées de fc
KR101962483B1 (ko) *	2010-11-17	2019-03-29	추가이 세이야쿠 가부시키가이샤	혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) *	2011-07-21	2014-07-29	Zoetis Llc	Interleukin-31 monoclonal antibody
US20140242077A1 (en)	2013-01-23	2014-08-28	Abbvie, Inc.	Methods and compositions for modulating an immune response
BR112016006502A2 (pt) *	2013-09-30	2017-09-19	Chugai Pharmaceutical Co Ltd	Método para a produção de molécula de ligação de antígeno usando-se fago auxiliar modificado
TWI652279B (zh) *	2013-11-11	2019-03-01	中外製藥股份有限公司	含改變的抗體可變區之抗原結合分子
KR102568808B1 (ko) *	2014-04-07	2023-08-18	추가이 세이야쿠 가부시키가이샤	면역활성화 항원 결합 분자
EP4632120A3 (fr) *	2014-11-11	2026-01-07	Chugai Seiyaku Kabushiki Kaisha	Bibliothèque de molécules de liaison à l'antigène comprenant une région variable d'anticorps modifié
US20180171017A1 (en) *	2015-06-05	2018-06-21	Chugai Seiyaku Kabushiki Kaisha	Combined use of immune activators
MX2019006954A (es) *	2016-12-20	2019-08-01	Hoffmann La Roche	Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
EP3720963A4 (fr) *	2017-12-05	2021-12-08	Chugai Seiyaku Kabushiki Kaisha	Molécule de liaison à l'antigène comprenant une région variable d'anticorps modifiée se liant à cd3 et cd137

2019
- 2019-09-27 KR KR1020217012569A patent/KR20210068079A/ko not_active Withdrawn
- 2019-09-27 SG SG11202101912UA patent/SG11202101912UA/en unknown
- 2019-09-27 PE PE2021000378A patent/PE20211072A1/es unknown
- 2019-09-27 MA MA053742A patent/MA53742A/fr unknown
- 2019-09-27 JP JP2021512587A patent/JP7519990B2/ja active Active
- 2019-09-27 CA CA3114154A patent/CA3114154A1/fr active Pending
- 2019-09-27 WO PCT/JP2019/038138 patent/WO2020067419A1/fr not_active Ceased
- 2019-09-27 TW TW108135110A patent/TW202028238A/zh unknown
- 2019-09-27 CN CN201980076578.6A patent/CN113166247A/zh active Pending
- 2019-09-27 MX MX2021003608A patent/MX2021003608A/es unknown
- 2019-09-27 EP EP19866533.3A patent/EP3856785A4/fr active Pending
- 2019-09-27 BR BR112021005722A patent/BR112021005722A2/pt not_active Application Discontinuation
- 2019-09-27 CR CR20210199A patent/CR20210199A/es unknown
- 2019-09-27 US US17/272,972 patent/US20210388087A1/en active Pending
- 2019-09-27 AU AU2019347412A patent/AU2019347412A1/en not_active Withdrawn
2021
- 2021-03-24 PH PH12021550662A patent/PH12021550662A1/en unknown
- 2021-03-24 IL IL281787A patent/IL281787A/en unknown
- 2021-03-25 CL CL2021000739A patent/CL2021000739A1/es unknown
- 2021-04-28 CO CONC2021/0005528A patent/CO2021005528A2/es unknown
2024
- 2024-05-23 JP JP2024083730A patent/JP7777183B2/ja active Active
2025
- 2025-11-14 JP JP2025194883A patent/JP2026021604A/ja active Pending

Also Published As

Publication number	Publication date
TW202028238A (zh)	2020-08-01
JP2022502010A (ja)	2022-01-11
BR112021005722A2 (pt)	2021-07-06
SG11202101912UA (en)	2021-04-29
EP3856785A4 (fr)	2022-07-06
CO2021005528A2 (es)	2021-07-30
US20210388087A1 (en)	2021-12-16
PE20211072A1 (es)	2021-06-09
PH12021550662A1 (en)	2021-12-13
JP7777183B2 (ja)	2025-11-27
KR20210068079A (ko)	2021-06-08
JP2026021604A (ja)	2026-02-10
AU2019347412A1 (en)	2021-05-27
JP2024109792A (ja)	2024-08-14
CL2021000739A1 (es)	2021-09-24
CA3114154A1 (fr)	2020-04-02
CR20210199A (es)	2021-06-11
JP7519990B2 (ja)	2024-07-22
IL281787A (en)	2021-05-31
WO2020067419A1 (fr)	2020-04-02
EP3856785A1 (fr)	2021-08-04
MX2021003608A (es)	2021-05-28
CN113166247A (zh)	2021-07-23

Publication	Publication Date	Title
EP3856785A4 (fr)	2022-07-06	Molécules de liaison à l'antigène capables de se lier à cd3 et cd137 mais pas simultanément
MA49039A (fr)	2020-02-12	Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
IL280004A (en)	2021-03-01	Antibody molecules that bind pd-l1 and cd137
FR26C1002I1 (fr)	2026-03-06	Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations
MA50613A (fr)	2020-08-12	Molécules de liaison spécifique à l'hpv
EP3891181A4 (fr)	2022-08-17	Molécules de liaison à cd3 et leurs utilisations
EP3408400A4 (fr)	2019-11-27	Protéines de liaison à l'antigène se liant à pd-l1
CL2023000896A1 (es)	2023-11-03	Receptores quiméricos de dll3 y métodos para su uso
EP4048309A4 (fr)	2024-02-21	Anticorps humanisés contre le ligand 1a de type tnf (tl1a) et leurs utilisations
MA54513A (fr)	2022-03-30	Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
EP4048701A4 (fr)	2024-05-29	Molécules de liaison anti-cd40 et anticorps bispécifiques les comprenant
EP3720963A4 (fr)	2021-12-08	Molécule de liaison à l'antigène comprenant une région variable d'anticorps modifiée se liant à cd3 et cd137
EP3802581A4 (fr)	2022-04-13	Protéines de liaison multispécifiques et améliorations de celles-ci
MA45680A (fr)	2019-05-22	Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123
EP3299383A4 (fr)	2019-01-23	MODIFICATION SPÉCIFIQUE DE L'ANTICORPS PAR UN PEPTIDE DE LIAISON À IgG
MA53094A (fr)	2021-05-12	Protéine de liaison à l'antigène anti-steap1
MX2019000476A (es)	2019-06-10	Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso.
UA120981C2 (uk)	2020-03-10	Антитіло, що зв'язується з il-8, та його застосування
WO2014159595A3 (fr)	2014-12-04	Anticorps humains dirigés contre nav1.7
CR20180154A (es)	2018-04-12	Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
HRP20220531T1 (hr)	2022-06-10	Varijabilni fragmenti antitijela koji se umeću i modificirane a1-a2 domene nkg2d liganda
MA47113A (fr)	2019-10-30	Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
IL285626A (en)	2021-09-30	Claudin 6 antibodies and uses thereof
EP2647706A4 (fr)	2015-04-22	Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène
EP3902840A4 (fr)	2022-09-21	Protéines multispécifiques de liaison à l'antigène pouvant se lier à cd19 et cd3, et leur utilisation